Nonalcoholic Steatohepatitis – Geographic Focus – China – Nonalcoholic Steatohepatitis – China In-Depth (China)
Nonalcoholic steatohepatitis (NASH) is a chronic illness that induces significant and sometimes fatal liver fibrosis; it is one of the primary causes of liver transplantation. In China, where the prevalence of NASH is the highest in the world, liver disease has become a significant public health concern as a result of a steep increase in the prevalence of diabetes and obesity. As of today, only off-label generic drugs are prescribed to treat the condition, but we anticipate the launch and gradual but substantial uptake of novel agents—semaglutide (Novo Nordisk’s Wegovy), denifanstat (TVB-2640) (Sagimet Biosciences), and lanifibranor (Inventiva Pharma)—during the forecast period. In view of the significant unmet medical need and the absence of approved disease-modifying treatments (DMTs) for NASH, China presents significant market potential for drug developers.
QUESTIONS ANSWERED
- What is the diagnosed prevalence of NASH, and how are NASH patients treated today? Do treatment management strategies differ between urban and rural China?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of NASH?
- What are the key market access considerations, and how are they likely to impact the uptake of emerging therapies for NASH in China?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
Content Highlights
Geographies: China.
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 hepatologists and gastroenterologists.
Epidemiology: Diagnosed prevalence of NASH in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key NASH therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase 3/PR: 2 drugs; Phase 2: 10+ drugs; coverage of select preclinical and Phase 1 products.
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Table of contents
Sahil Arora, M.B.A., Healthcare Research & Data Analyst, China In-Depth. Prior to joining Clarivate, Mr. Arora was a senior associate on the Intelligence and Insights team at Prescient Healthcare Group. He has several years of experience in competitive intelligence, key opinion leader (KOL) identification, KOL profiling, and social media footprint analysis. He holds a master’s degree in pharmaceutical management from NIPER Mohali in India.
Ansuman Swain, B.D.S., M.P.H., Epidemiologist, Epidemiology. As part of his M.P.H. curriculum, he worked as an intern at the National Health Mission in Odisha, India, where he observed the implementation of the RBSK program. Mr. Swain is a graduate in dentistry from KIIT University in Odisha and holds an M.P.H. degree from Manipal Academy of Higher Education in Karnataka, India, with a specialization in global health from Maastricht University in the Netherlands.